Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don't lose sight of what's important ...

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Aug 19, 2021 7:42pm

133 Views

Post# 33737700

RE:Don't lose sight of what's important ...

so do AME First before waist time on new phase 11. But sure they will drag out to collect oaycheque for another 2 years before we lose everything .

MrMugsy wrote: Can the dose go lower?
The market has hated this unknown so we need to figure it out.
MIght need AME #2 as we look at 75,50,25 mg
Might need AME #3 as we look at 25,15,10 mg if we still don't know the lowest possible dose.
Either way, there are higher dose and lower dose options for this drug.

Nice to see that a replacement for 352 is also in the cards for this one - with potential for fast-track.

5 weeks - get an idea of where we are going.
Is the liver constantly bathing in Naproxen?
Just might be the case.

Once we have it figured out and on our way - hoping we are further derisked and much more valuable to a partner.